1. 301 First-in-human phase I dose-escalation study of a MET/AXL/FGFR inhibitor, S 49076, in patients with advanced solid tumors. (September 2015) Authors: Azaro, A.; Rodon, J.; Herranz, M.; Nuciforo, P.; Prudkin, L.; Lopez-Busto, N.; Balandraud, S.; Cattan, V.; Jacquet-Bescond, A.; Marfai, L.; Pauly, J.; Postel-Vinay, S.; Hollebecque, A.; Soria, J.C. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S54 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer. (December 2016) Authors: Massard, C.; Azaro, A.; Soria, J.C.; Lassen, U.; Le Tourneau, C.; Smith, C.; Ohnmacht, U.; Oakley, G.; Patel, B.K.R.; Yuen, E.S.M.; Benhadji, K.A.; Rodon, J. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S15 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Early interventions to detect potential drug–drug interactions on patient eligibility for phase 1 clinical trials. (December 2016) Authors: Azaro, A.; Ghiglione, L.; Valdivia, C.; Munné, M.; Renedo, B.; Sabaté, N.; Alcalde, M.; Braña, I.; Hierro, C.; Martin-Liberal, J.; Ochoa de Olza, M.; Argiles Martínez, G.; Vilaró, M.; Tabernero, J.; Rodon, J. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S42 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗